These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22173438)

  • 1. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
    Koprowska K; Czyż M
    Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
    Banaszynski M; Kolesar JM
    Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
    J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
    Jones C; Zhao Z; Barber B; Bagijn M; Corrie P; Saltman D
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):862-6. PubMed ID: 25988349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targets in the treatment of advanced melanoma: new first-line treatment options.
    Culos KA; Cuellar S
    Ann Pharmacother; 2013 Apr; 47(4):519-26. PubMed ID: 23548648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab and vemurafenib: two different routes for targeting melanoma.
    Burgeiro A; Mollinedo F; Oliveira PJ
    Curr Cancer Drug Targets; 2013 Oct; 13(8):879-94. PubMed ID: 23862981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
    Wolchok J
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii15-21. PubMed ID: 22918923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in metastatic melanoma: toward a clinical breakthrough?
    Julia F; Thomas L; Dumontet C; Dalle S
    Anticancer Agents Med Chem; 2010 Nov; 10(9):661-5. PubMed ID: 21235437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic strategies and systemic treatment of brain melanoma metastases].
    Durando X; Mansard S; Daste A; Gimbergues P; Brocard L; Magné N; Thivat E
    Bull Cancer; 2013 Jan; 100(1):23-8. PubMed ID: 22889847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide for the treatment of metastatic melanoma: a systematic review.
    Quirt I; Verma S; Petrella T; Bak K; Charette M
    Oncologist; 2007 Sep; 12(9):1114-23. PubMed ID: 17914081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
    Teimouri F; Nikfar S; Abdollahi M
    Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
    Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
    J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
    Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
    Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.